Related Experiment Video

Updated: Jun 28, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.9K

Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

Karen M Yun1, Lyudmila Bazhenova1

  • 1Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, CA 92093, USA.

Cancers
|April 13, 2024
PubMed

Insights

Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options. This review explores advancements in targeted therapies, offering new hope for advanced unresectable MPM patients.

Area of Science:

  • Oncology
  • Genomics
  • Thoracic Surgery

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive cancer with diverse molecular and pathological subtypes.
  • Current treatments for advanced, unresectable MPM are primarily cytotoxic chemotherapy and immunotherapy, with limited efficacy.
  • Identifying actionable therapeutic targets in MPM has been challenging due to frequent alterations in tumor suppressor genes.

Purpose of the Study:

  • To review recent advancements in targeted systemic therapies for MPM.
  • To discuss the current landscape and future directions of targeted treatment strategies for advanced MPM.

Main Methods:

  • Literature review of recent studies on MPM genomics and targeted therapies.
  • Analysis of clinical trial data for novel targeted therapeutics in MPM.
  • Discussion of challenges and opportunities in MPM targeted therapy development.

Main Results:

  • Understanding of MPM's genomic landscape has significantly improved.
  • Novel targeted therapeutics are emerging and entering early-phase clinical trials.
  • Progress in targeted therapy discovery for MPM has lagged behind other solid tumors.

Conclusions:

  • Targeted therapies represent a promising frontier for advanced MPM treatment.
  • Continued research into MPM's genetic signatures is crucial for developing effective therapies.
  • Future strategies will likely focus on personalized approaches based on individual tumor profiles.
Keywords:
BAP1NF2malignant pleural mesotheliomamesothelintargeted therapy

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.9K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
203